Approval · Notice of Compliance 22265 · 2019
ILEVRO: Notice of Compliance 22265
Issued June 11, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22265
- Date
- June 11, 2019
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- To introduce a change in the position of the DIN on the outer folding box, as well to update the labels to comply with the PLL regulations
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ILEVRO | Not yet assigned | — |
Medicinal ingredients
- NEPAFENAC 0.3 PER